HALT: A trial of stereotactic body radiotherapy with targeted drug treatment in advanced non small lung cancer

Enrolling participants   

What is the study about? 

HALT investigates a treatment option for advanced non-small cell lung cancer. 

Non-small cell lung cancer is the most common type of lung cancer, affecting around 9 in 10 of people diagnosed. Some people with this type of cancer have certain genetic abnormalities, or mutations, in their cancer cells which can be treated with drugs called tyrosine kinase inhibitors (TKI). 

Tyrosine kinase inhibitors often work well to start with but then stop working as well because cancer cells build a resistance to them. This can lead to areas of cancer growing, or progressing, around the body. The HALT trial is looking at whether treating small areas of progression with a type of very precisely targeted radiotherapy called stereotactic body radiotherapy (SBRT) can help the tyrosine kinase inhibitor work better for longer.

The results of the HALT trial will be used to help decide if SBRT would be a helpful treatment for small areas of progression in people with this type of cancer in future.